Back to results
US 2025/0026751 A1Published application
Cocrystal
AssigneeTakeda Pharmaceutical Company Limited
InventorsKentaro IWATA, Yukihiro IKEDA
Life of this patent
Estimating the term…
Abstract
Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.
Claims21
-12. (canceled)
A cocrystal of:
- (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide;
- and
- (2) L-malic acid,
- wherein the cocrystal is characterized by a powder X-ray diffraction pattern comprising characteristic peaks at the lattice spacing (d) of 11.7±0.2, 10.0±0.2, 8.6±0.2, 5.8±0.2 and 4.9±0.2 angstroms.
1 more element
A cocrystal of:
- (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4--yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide;
- and
- (2) L-tartaric acid,
- wherein the cocrystal is characterized by a powder X-ray diffraction pattern comprising characteristic peaks at the lattice spacing (d) of 12.0±0.2, 10,1±0.2, 8.7±0.2, 5.9±0.2 and 4.9±0.2 angstroms.
1 more element
Dependencies are inferred from the claim text.